United Therapeutics (UTHR)

Add to Watchlists
Create an Alert
115.32 -2.01  -1.71% NASDAQ Jun 18, 15:33 Delayed 2m USD

United Therapeutics Research and Development Expense (Quarterly):

35.70M for March 31, 2018
View 4,000+ financial data types
View Full Chart

United Therapeutics Research and Development Expense (Quarterly) Chart

Export Data
Save Image
Print Image

United Therapeutics Historical Research and Development Expense (Quarterly) Data

View and export this data going back to 1999. Start your Free Trial
Export Data Date Range:
Data for this Date Range  
March 31, 2018 35.70M
Dec. 31, 2017 113.60M
Sept. 30, 2017 55.00M
June 30, 2017 59.80M
March 31, 2017 36.20M
Dec. 31, 2016 66.90M
Sept. 30, 2016 45.90M
June 30, 2016 35.20M
March 31, 2016 0.40M
Dec. 31, 2015 75.90M
Sept. 30, 2015 9.60M
June 30, 2015 49.40M
March 31, 2015 110.20M
Dec. 31, 2014 71.43M
Sept. 30, 2014 118.88M
June 30, 2014 39.74M
March 31, 2014 12.45M
Dec. 31, 2013 121.55M
Sept. 30, 2013 72.75M
June 30, 2013 54.62M
March 31, 2013 50.43M
Dec. 31, 2012 37.48M
Sept. 30, 2012 65.16M
June 30, 2012 37.10M
March 31, 2012 33.66M
Dec. 31, 2011 48.64M
Sept. 30, 2011 59.43M
June 30, 2011 24.24M
March 31, 2011 47.71M
Dec. 31, 2010 61.92M
Sept. 30, 2010 40.34M
June 30, 2010 28.59M
March 31, 2010 34.87M
Dec. 31, 2009 41.03M
Sept. 30, 2009 31.55M
June 30, 2009 28.65M
March 31, 2009 20.96M
Dec. 31, 2008 179.75M
Sept. 30, 2008 19.21M
June 30, 2008 19.14M
March 31, 2008 21.08M
Dec. 31, 2007 17.71M
Sept. 30, 2007 19.56M
June 30, 2007 17.97M
March 31, 2007 28.11M
Dec. 31, 2006 18.34M
Sept. 30, 2006 11.92M
June 30, 2006 12.61M
March 31, 2006 14.70M
Dec. 31, 2005 9.463M

There is no data for the selected date range.

An error occurred. Please try again by refreshing your browser or contact us with details of your problem.

About R&D Expense

R&D expenses are a line item from many companies' income statements.

R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More


UTHR Research and Development Expense (Quarterly) Benchmarks

Nektar Therapeutics 99.42M
Aerie Pharmaceuticals 12.97M
Ultragenyx Pharmaceutical 75.50M

UTHR Research and Development Expense (Quarterly) Range, Past 5 Years

Minimum 0.40M Mar 2016
Maximum 121.55M Dec 2013
Average 59.26M

UTHR Research and Development Expense (Quarterly) Excel Add-In Codes

  • Metric Code: r_and_d_expense
  • Latest data point: =YCP("UTHR", "r_and_d_expense")
  • Last 5 data points: =YCS("UTHR", "r_and_d_expense", -4)

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.




Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.